Ou Yangwenshan, Chen Shanbin, Ren Fazheng, Zhang Ming, Ge Shaoyang, Guo Huiyuan, Zhang Hao, Zhao Liang
Beijing Advanced Innovation Center for Food Nutrition and Human Health, College of Food Science and Nutritional Engineering, China Agricultural University, Beijing, China.
Key Laboratory of Functional Dairy, College of Food Science and Nutritional Engineering, China Agricultural University, Beijing, China.
Front Microbiol. 2019 Feb 21;10:324. doi: 10.3389/fmicb.2019.00324. eCollection 2019.
The benefits of probiotics for constipation are widely accepted, but the mechanisms involving gut metabolites are unclear. In this study, we investigated the effects of strain Shirota (LcS) on constipated patients and revealed that a metabolite mediator is involved in the LcS-induced constipation alleviation. Sixteen constipated patients and 22 non-constipated participants were recruited. The subjects consumed 100 mL of an LcS beverage (10 CFU/mL) per day for 28 days. The fecal non-volatile metabolites were determined by GC/MS, and the targeted metabolites were further verified in a constipated mouse model. In constipated patients, LcS intervention significantly improved defecation frequency (from 4.81 to 7.81 times per week, < 0.05), stool consistency (from 2.52 to 3.68, < 0.05) and constipation-related symptoms. A total of 14 non-volatile fecal metabolites were obtained as potential constipation-related metabolites that were regulated by LcS. Among these metabolites, pipecolinic acid (PIPA) had a significant positive correlation with defecation frequency in constipated patients. PIPA significantly promoted the small intestinal propulsive rate (from 25.45 to 39.68%) and increased the number of fecal pellets (from 30.38 to 57.38 pellets) in constipated mice ( < 0.05). The 5-hydroxytryptamine (5-HT) and acetylcholine (ACh) in colonic tissue may be partly involved in PIPA-mediated constipation alleviation. In conclusion, PIPA was a metabolic mediator in the gut that participated in LcS-induced constipation alleviation.
益生菌对便秘的益处已被广泛认可,但其涉及肠道代谢物的机制尚不清楚。在本研究中,我们调查了鼠李糖乳杆菌(LcS)菌株对便秘患者的影响,并揭示了一种代谢介质参与了LcS诱导的便秘缓解过程。招募了16名便秘患者和22名非便秘参与者。受试者每天饮用100 mL的LcS饮料(10 CFU/mL),持续28天。通过气相色谱/质谱法测定粪便中的非挥发性代谢物,并在便秘小鼠模型中进一步验证目标代谢物。在便秘患者中,LcS干预显著改善了排便频率(从每周4.81次提高到7.81次,P<0.05)、粪便稠度(从2.52提高到3.68,P<0.05)以及与便秘相关的症状。共获得14种非挥发性粪便代谢物作为受LcS调节的潜在便秘相关代谢物。在这些代谢物中,哌啶酸(PIPA)与便秘患者的排便频率呈显著正相关。PIPA显著提高了便秘小鼠的小肠推进率(从25.45%提高到39.68%),并增加了粪便颗粒数量(从30.38个增加到57.38个)(P<0.05)。结肠组织中的5-羟色胺(5-HT)和乙酰胆碱(ACh)可能部分参与了PIPA介导的便秘缓解过程。总之,PIPA是肠道中的一种代谢介质,参与了LcS诱导的便秘缓解过程。